Responses
Multiple sclerosis
Research paper
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study
Compose a Response to This Article
Other responses
No responses have been published for this article.